Cytodyn Inc (CYDY)

[Bunny3999]

Leronlimab in Russia:

https://gmpnews.ru/2020/05/leronlimab-pokazyvaet-vysokuyu-effektivnost-pri-lechenii-covid-19/

Leronlimab is highly effective in treating COVID-19
05/26/2020632

The drug leronlimab (leronlimab) from the American company CytoDyn, specializing in the development of therapy with monoclonal antibodies, is a promising candidate for the treatment of COVID-19 . Experts at GlobalData , a research firm, forecast that its peak sales could reach $ 747 million in 2026, which puts it in second place after remdesivir from Gilead Sciences.

Leronlimab is a humanized monoclonal antibody IgG4 that blocks the CCR5 cell receptor, which plays a crucial role in HIV infection, tumor growth (metastasis) and other diseases, including non-alcoholic steatohepatitis. The drug was originally developed for the treatment of human immunodeficiency virus (HIV). Leronlimab has FDA Fast Track status as part of combination antiretroviral therapy for HIV patients and metastatic triple negative breast cancer therapy.

According to GlobalData, leronlimab behind in the evaluation of remdesivira because the drug from Gilead already has permission to FDA for an emergency use in emergencies in the US, Japan, the drug is approved for COVID-19 treatment under the tradename Veklury® and that is not important enough, remdesivir is being developed by one of the ten leading biotechnological companies in the USA - Gilead, which is the market leader in antiviral drugs.

Situation commented Joanna Swanson (Johanna Swanson), a grocery manager GlobalData:

“Leronlimab is currently in phase III clinical trials, making it one of the leading drugs in the research phase with respect to COVID-19. Leronlimab is being studied in two clinical trials. One has 75 participants, the other has 390.

A small observational study recently showed that Leronlimab can reduce viral load and help restore the immune system of patients with COVID-19. According to IncellDx, in critically ill patients there was a sharp restoration of immunity and extubation within seven days after treatment.

Although these results are promising, they are based on a small sample of only ten patients. To confirm these data, larger placebo-controlled clinical trials are needed.

Leronlimab is currently undergoing two clinical trials based on the drug’s ability to mitigate the cytokine storm. ”

Recall that on May 18, CytoDyn announced that it intends to submit to the FDA a phase III test report to test the design of the study, which consists in comparing the efficacy of leronlimab and remdesivir , as well as in combination with remdesivir .

CytoDyn has already received a guarantee from the manufacturer that this year more than 1 million bottles will be available, with a subsequent increase in production to 2-3 million bottles of the drug.